FDA Approves Esketamine Nasal Spray as Standalone Treatment for Depression
FDA Approves Spravato Nasal Spray as Standalone Treatment for Major Depressive Disorder In a groundbreaking move, the U.S. food and Drug Governance (FDA) has approved a supplemental new drug request for Spravato (esketamine) nasal spray, allowing it to be used as a standalone treatment for adults with major depressive disorder (MDD) who have not responded … Read more
